Mazyar Shadman, MD, on Growing Research Trends in LBCL
The associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.
“At the end of the day, retrospective studies are important but only affirmative in clinical decisions, and one needs to consider the limitations that come with such an analysis. So, we want to make sure that access to CAR-T is improved and those patients get to CAR-T. But there may be patients who can benefit from this data, in terms of knowing about their additional choices for therapy.”
Auto-hematopoietic stem cell transplant (HSCT) is associated with a lower relapse rate and an improved progression-free survival compared to chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed large B-cell lymphoma (LBCL) who achieve a complete or partial response with bridging chemotherapy.
These data, from a retrospective analysis, were presented by Mazyar Shadman, MD, MPH, associate professor, clinical research division, and attending physician, hematologic malignancies, Fred Hutch Cancer Center, and associate professor, medical oncology division, University of Washington School of Medicine, at the
CGTLive spoke with Shadman to learn more about the importance of the new findings and the takeaways that clinicians should take from them. He discussed more research he would like to see, as well as other research he worked on presented at ASH on ibrutinib and zanubrutinib. He also discussed research trends from 2023, including a focus on combination and sequencing therapies.
REFERENCE
Shadman M, Wooahn K, Kaur M, et al. Autologous transplant (auto-HCT) is associated with improved clinical outcomes compared to CAR-T therapy in patients (pts) with large B-cell lymphoma (LBCL) achieving a complete remission. Presented at: 2023 ASH Annual Meeting, December 9-12; San Diego, California. Abstract #781
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025